Top 5 Takeaways Increased Incidence of Post-COVID Conditions: Adults who survived COVID-19 are at a higher risk of developing conditions such as pulmonary embolism and respiratory symptoms, with 38% of

Top 5 Takeaways Widespread Outbreak: Early 2021 witnessed a multistate outbreak of listeriosis with 13 cases across four states, predominantly affecting Hispanic populations, leading to 12 hospitalizations and one death.

Top 5 Takeaways New Vaccine Option: JYNNEOS, a replication-deficient Vaccinia virus vaccine licensed in 2019, is now recommended by ACIP for preexposure prophylaxis against orthopoxviruses, offering an alternative to ACAM2000.

Top 5 Takeaways Increase in Group A Streptococcus Bacteremia: The University of Vermont Medical Center noted a substantial rise in cases of group A streptococcal bloodstream infections during 2022–2023, primarily

Top 5 Takeaways New Vaccination Recommendation: As of February 28, 2024, the Advisory Committee on Immunization Practices (ACIP) recommends an additional dose of the updated (2023–2024 Formula) COVID-19 vaccine for

Top 5 Takeaways Rapid Outbreak Following School Event: An outbreak of influenza A(H3N2) occurred among attendees of a school banquet, with 41% of students reporting symptoms within a median of

Top 5 Takeaways Higher barriers to healthcare for adults with epilepsy: Compared to adults without epilepsy, those with active or inactive epilepsy face more significant challenges in accessing necessary medical

Top 5 Takeaways Significant Decline During Early Pandemic: The early phase of the COVID-19 pandemic saw a sharp decrease in seizure- or epilepsy-related emergency department (ED) visits across all age

Top 5 Takeaways Link between SDOH, HRSNs, and Mammography: Women experiencing more adverse Social Determinants of Health (SDOH) and Health-Related Social Needs (HRSNs) reported lower mammography use, highlighting significant barriers

Top 5 Takeaways New Vaccine Approval: The FDA has approved the Pfizer Pentavalent Meningococcal Vaccine (MenACWY-TT/MenB-FHbp, branded as Penbraya) for individuals aged 10–25 years to protect against serogroups A, B,